The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
Gopalappa, Chaitra; Stover, John; Shaffer, Nathan; Mahy, Mary.
; 28 Suppl 1: S5-14, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24468947
Accelerating HIV-1 Vaccine Efficacy Trials.
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project.
The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy "Test-and-Offer" Era.
Measurement, "scriptural economies," and social justice: governing HIV/AIDS treatments by numbers in a fragile state, the Central African Republic (CAR).
Cost-effectiveness analysis along the continuum of HIV care: how can we optimize the effect of HIV treatment as prevention programs?
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
The importance of assessing out-of-pocket payments when the financing of antiretroviral therapy is transitioned to domestic funding: findings from Vietnam.
HIV antiretroviral medication stock-outs in Ghana: contributors and consequences.
The cost of accessing infant HIV medications and health services in Uganda.
Health prevention in the era of biosocieties: a critical analysis of the 'Seek-and-Treat' paradigm in HIV/AIDS prevention.